Financial Performance - The company's operating revenue for 2022 was ¥267,535,512.07, a decrease of 75.58% compared to ¥1,095,481,169.58 in 2021[24]. - The net profit attributable to shareholders was -¥454,951,605.22, representing a decline of 247.84% from ¥307,740,641.70 in the previous year[24]. - The cash flow from operating activities showed a net outflow of -¥36,774,850.90, a decrease of 149.53% compared to a positive cash flow of ¥74,254,869.02 in 2021[24]. - The basic and diluted earnings per share were both -¥0.30, down 250.00% from ¥0.20 in 2021[24]. - Total assets at the end of 2022 were ¥3,268,933,980.20, a decrease of 13.15% from ¥3,764,024,801.92 at the end of 2021[24]. - The net assets attributable to shareholders decreased by 18.79% to ¥1,958,663,035.81 from ¥2,411,882,951.96 in 2021[24]. - The company reported a significant loss from fair value changes of financial assets amounting to -¥39,168,793.71 in 2022[32]. - The total non-recurring losses amounted to -¥141,303,257.21, compared to a gain of ¥642,139,790.78 in 2021[32]. - The company reported a substantial loss of 217,326,147.78 CNY due to the impairment of receivables from a subsidiary, with 106,011,694.89 CNY allocated to the profit attributable to the parent company's owners[34]. - The company reported a net profit of -¥373,507,047.48 in 2022, a significant decline from a profit of ¥203,048,220.29 in 2021[74]. Business Transformation and Strategy - The company underwent a business transformation in 2021, shifting its main operations from pesticide production and sales to the research and development of pesticide formulations, brand operation, agricultural e-commerce, and petrochemical supply chain[23]. - The company aims to transform into a leader in the agricultural e-commerce sector through the development of 288 segments and a focus on end-user services[49]. - The company is focusing on the development of new biological agricultural products, including bio-pesticides and bio-fertilizers, to meet market demand and enhance competitiveness[92]. - The company has outlined its 2023 operational strategy, emphasizing quality improvement and the establishment of a comprehensive agricultural service platform[94]. - The company plans to focus on the "Two Increases and Two Goods" strategy in its functional agriculture division, aiming to enhance production and income while ensuring product quality[93]. Research and Development - The company has applied for 19 domestic invention patents in the field of biostimulants, with 11 granted and 6 PCT international patents applied for, including one awarded in Australia[46]. - The company has invested ¥500 million in the petrochemical warehousing and logistics project, which spans 390 acres and has a total storage capacity of 308,000 cubic meters[50]. - The company reported a significant reduction in R&D expenses, which fell by 92.69% from CNY 28,867,114.55 in 2021 to CNY 2,110,866.41 in 2022[66]. - The number of R&D personnel decreased by 73.33% from 30 in 2021 to 8 in 2022, with R&D personnel now accounting for 26.67% of the workforce[68]. - R&D investment decreased significantly to ¥2,913,405.89 in 2022 from ¥45,388,085.70 in 2021, a decline of 93.58%[69]. Market and Industry Trends - The agricultural market in China maintained a steady growth trend in 2022, despite challenges from the Russia-Ukraine conflict, with significant fluctuations in raw material prices[38]. - Over 50% of pesticide varieties experienced a year-on-year price decline of 20% to 30%, with some products dropping by as much as 50%[40]. - The agricultural industry is expected to benefit from favorable government policies and the "14th Five-Year" national pesticide industry development plan, enhancing the industry's support for agricultural production[39]. - The company is focusing on the development of biostimulants, which are expected to play a significant role in increasing crop yields and maintaining agricultural ecological balance[41]. Governance and Compliance - The company maintains complete independence from its controlling shareholders in terms of business, assets, personnel, and finance, with no shared assets or financial dependencies[102][103][104][105]. - The company has established an independent financial accounting department and a separate accounting system, ensuring independent financial decision-making[105]. - The company has a robust governance structure that complies with the Company Law and relevant regulations, with no significant discrepancies noted[101]. - The company has established a comprehensive internal control system that is effective and suitable for its operations[141]. - The internal control audit report received a clean opinion with an emphasis on certain matters[146]. Legal and Regulatory Issues - The company has faced challenges in managing its subsidiary, Shijiazhuang Ruikai Chemical Co., Ltd., due to unresolved disputes since November 1, 2020, affecting its operational control[153]. - The company is involved in multiple lawsuits with a total amount of approximately 87.71 million yuan (8,771,000 yuan) pending in various stages of litigation[179]. - The company has recognized a provision for estimated liabilities amounting to approximately 2.8 million yuan (280,000 yuan) related to ongoing litigation[180]. - The company has faced a total of 318 labor-related disputes, with 1,145.52 thousand yuan (1,145,520 yuan) in estimated liabilities recognized[180]. Shareholder and Dividend Policies - The profit distribution policy stipulates that at least 10% of the distributable profit should be allocated to shareholders annually, ensuring a stable and continuous distribution approach[133]. - The company prioritizes cash dividends, with a requirement that the cash distributed should not be less than 10% of the current year's distributable profit[133]. - The company did not propose any cash dividend distribution for the reporting period, despite having positive distributable profits[137]. - The company has established a shareholder return plan to enhance the transparency of cash dividends and meet investor expectations[133]. Future Outlook - Future outlook indicates a focus on expanding market presence and enhancing product offerings, with plans to invest in new technologies and product development[110]. - Jiangsu Huifeng aims to enhance its research and development capabilities, particularly in the agricultural biotechnology sector, to support long-term growth[110]. - The company anticipates a continued upward trend in revenue growth, projecting a target of 66.41% increase in the upcoming fiscal year[109]. - Jiangsu Huifeng plans to leverage digital marketing strategies to enhance customer engagement and drive sales growth[110].

出席本次业绩说明会的人员有：总经理张晓波先生，公司副董事长、副总经理裴 柏平先生，董事、副总经理兼财务负责人周京先生，副总经理兼董事会秘书孙永良先 生，独立董事杨兆全先生。 欢迎广大投资者积极参与，特此公告 。 江苏辉丰生物农业股份有限公司董事会 证券代码：002496 证券简称：辉丰股份 公告编号：2023-018 江苏辉丰生物农业股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 江苏辉丰生物农业股份有限公司（以下简称"公司"）第八届董事会第二十三次 会议审议通过了《2022年年度报告及其摘要》，相关公告已于2023年4月28日刊登于巨 潮资讯网（www.cninfo.com.cn）及《证券时报》、《中国证券报》，敬请投资者查阅。 公司将于2023年5月12日（星期五）15:00～17:00 通过全景网提供的网上平台举 办2022年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可 登陆"全景•路演天下"（http://rs.p5w.net）参与本次年度业绩说明会。 二○二三年四月二十六日 ...

江苏辉丰生物农业股份有限公司 证券代码：002496 证券简称：辉丰股份 江苏辉丰生物农业股份有限公司投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |----------------|------------------|---------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 □媒体采访 | | 投资者关系活动 | □ 业绩说明会 | □新闻发布会 □路演活动 | | 类别 | □现场参观 | □其他 （请文字说明其他活动内容） | | | | 长江证券：马太、鞠龙 | | 参与单位名称 | | 天风证券：吴頔 申万宏源：陈俊杰 | | 及人员姓名 | | 工银瑞信：高京霞 嘉实基金：付赫 华夏基金：杨晋、蒋文超 | | | 兴银基金：蔡国亮 | | | 时 间 | 2017.10.27 | | | | | | | 地 点 | 公司会议室 | | | 接待人员姓名 | | 董事长：仲汉根 董事会秘书：孙永良 | | 投资者关系活动 | 1 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥66,265,164.41, representing a decrease of 58.30% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥27,839,725.19, which is a 264.79% increase in loss compared to the previous year[5]. - The basic earnings per share were -¥0.0185, reflecting a 264.79% increase in loss compared to -¥0.0120 in the same period last year[5]. - The company recorded a loss of ¥41,400,260.42 after deducting non-recurring gains and losses, which is a 40.18% increase in loss compared to the previous year[5]. - The net profit for Q3 2022 was -94,287,267.67 CNY, a significant decline compared to a net profit of 504,574,026.34 CNY in the same period last year[30]. - Operating profit for Q3 2022 was -88,753,084.14 CNY, down from 586,627,873.49 CNY in Q3 2021[30]. - The company reported a total comprehensive income of -92,899,627.44 CNY for Q3 2022, compared to 306,092,720.32 CNY in Q3 2021[31]. - The basic and diluted earnings per share for Q3 2022 were both -0.0440 CNY, down from 0.3558 CNY in the previous year[31]. Revenue and Costs - The company reported a significant decrease in operating income, down 79% year-on-year to ¥203,046,883.34, primarily due to a reduction in the production and sales of original medicines and formulations following a major asset restructuring in May 2021[11]. - Total operating revenue for the period was CNY 203,046,883.34, a significant decrease from CNY 958,363,096.96 in the previous period, representing a decline of approximately 78.8%[29]. - Total operating costs amounted to CNY 278,430,091.62, down from CNY 1,086,940,213.94 in the previous period, indicating a reduction of about 74.3%[29]. Cash Flow and Assets - The net cash flow from operating activities was -¥13,280,280.62, indicating a 60.85% improvement compared to -¥19,846,276.53 in the previous year[5]. - The net cash flow from operating activities was negative at RMB -13,280,280.62, a 61% decline compared to RMB -8,256,295.75, driven by increased prepayment expenditures in trade business[12]. - The net cash flow from investing activities decreased by 82% to RMB 93,380,418.23 from RMB 509,605,414.32, primarily due to the receipt of equity transfer payments in the previous year[12]. - The net cash flow from financing activities improved by 95% to RMB -40,383,881.24 from RMB -760,298,853.54, as the company repaid bank loans and non-related party borrowings in the prior period[12]. - The company's cash and cash equivalents increased to CNY 194,693,419.11 from CNY 155,665,836.67, reflecting a growth of approximately 25%[25]. - Cash and cash equivalents at the end of Q3 2022 totaled 133,302,694.68 CNY, an increase from 78,729,166.42 CNY at the end of Q3 2021[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,675,746,320.73, a decrease of 2.35% from the previous year[5]. - Total assets as of September 30, 2022, were CNY 3,675,746,320.73, down from CNY 3,764,024,801.92 at the beginning of the year, indicating a decrease of about 2.4%[27]. - Total liabilities increased slightly to CNY 1,546,597,917.93 from CNY 1,543,377,061.48, reflecting a marginal increase of about 0.1%[27]. - The company's equity attributable to shareholders decreased to CNY 2,348,410,977.42 from CNY 2,411,882,951.96, a decline of approximately 2.6%[27]. - The company’s non-current assets totaled CNY 2,886,901,471.11, down from CNY 2,996,051,127.12, indicating a decrease of about 3.7%[26]. - The company’s total current liabilities increased to CNY 1,238,486,087.63 from CNY 1,204,148,121.23, representing an increase of approximately 2.8%[27]. Expenses - Management expenses decreased by 61% to RMB 92,861,875.40 from RMB 241,161,139.35, primarily due to the reduction in pharmaceutical and formulation production and sales following a major asset restructuring completed in May 2021[12]. - R&D expenses plummeted by 92% to RMB 1,569,090.22 from RMB 20,833,795.06, attributed to decreased investment in pharmaceutical R&D after the asset restructuring[12]. - The company incurred financial expenses of 17,478,131.99 CNY in Q3 2022, compared to 13,819,607.29 CNY in the same period last year[30]. - The total investment income for Q3 2022 was 13,722,037.41 CNY, a decrease from 703,680,377.78 CNY in Q3 2021[30]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 44,445, with the largest shareholder, Zhang Hangen, holding 31.19% of the shares[14]. Legal and Regulatory Issues - The company is facing ongoing litigation related to asset disposals and shareholder agreements, with significant financial implications pending resolution[17][18].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥136.78 million, a decrease of 82.89% compared to ¥720.62 million in the same period last year[26]. - The net profit attributable to shareholders of the listed company was a loss of approximately ¥38.42 million, down 107.06% from a profit of ¥545.30 million in the previous year[26]. - The basic earnings per share for the reporting period was -¥0.0255, a decline of 107.07% compared to ¥0.3617 in the same period last year[26]. - The total revenue for the period was ¥136,781,718.93, a decrease of 82.89% compared to ¥799,457,434.68 in the same period last year[44]. - The net profit for the first half of 2022 was a loss of CNY 47,685,516.38, compared to a profit of CNY 527,077,747.14 in the first half of 2021[156]. - The company's gross profit margin was approximately -32.5% for the first half of 2022, indicating a decline from previous performance[156]. - The total comprehensive income for the first half of 2022 was a loss of CNY 47,355,834.80, contrasting with a profit of CNY 328,526,236.26 in the first half of 2021[157]. - The total comprehensive income for the period was 15.849 billion yuan, showing a significant increase compared to the previous period[171]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥3.70 billion, a decrease of 1.66% from ¥3.76 billion at the end of the previous year[26]. - The total liabilities decreased to CNY 1,526,618,005.74 from CNY 1,543,377,061.48, indicating a reduction of about 1.1%[149]. - The company's cash and cash equivalents were CNY 151,222,040.65, down from CNY 155,665,836.67, representing a decline of approximately 2.9%[147]. - The total equity decreased to CNY 2,046,836,804.97 from CNY 2,096,567,684.49 in the previous year[156]. - The total owner's equity decreased to CNY 2,175,022,705.09 from CNY 2,220,647,740.44, reflecting a decline of approximately 2.0%[149]. Cash Flow - The cash flow from operating activities showed a net outflow of approximately ¥66.38 million, a significant decline of 266.29% compared to an outflow of ¥20.07 million in the previous year[26]. - The net cash flow from operating activities was -¥66,375,688.54, an increase of 266.29% compared to -¥18,121,169.70, mainly due to an increase in trade-related prepayments and inventory[42]. - The total cash inflow from financing activities was 202,521,540.25 CNY, down from 503,091,794.40 CNY in the previous period, reflecting a decline of approximately 59.8%[165]. - The net cash flow from financing activities was 84,327,005.20 CNY, contrasting with a net outflow of -660,508,338.31 CNY in the previous period, showing a recovery in financing cash flow[165]. Investments and Research - The company has applied for 19 domestic invention patents in the bio-stimulant sector, with 6 granted and 6 PCT international invention patents applied for, including in Australia[37]. - The company has allocated 1.7 billion yuan for research and development, which is 7.5% of total revenue[172]. - The company has initiated research and development for new products aimed at improving operational efficiency and market competitiveness[175]. Operational Risks and Challenges - The company faces operational, safety, and environmental risks, which investors are advised to consider[6]. - The ongoing COVID-19 pandemic has affected business operations and market demand for biological stimulants, prompting the company to adapt its outreach strategies[63]. - The company faced operational risks due to the transition of its agricultural chemical business, which may lead to a decline in revenue scale in the short term[62]. Shareholder and Equity Information - The total number of common shareholders at the end of the reporting period is 44,522[134]. - The largest shareholder, Zhong Hangen, holds 32.01% of the shares, totaling 482,631,953 shares[135]. - The company has a total of 485,957,311 shares held by its directors and senior management, with no changes in holdings during the reporting period[137]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[138]. Compliance and Governance - The semi-annual financial report was not audited, indicating potential limitations in financial oversight[80]. - The financial statements reflect the company's adherence to accounting standards, ensuring a true and complete representation of its financial status[186]. - The financial report was approved by the board on August 24, 2022, indicating timely governance and oversight[181]. Strategic Plans - The company plans to enhance its sales team and optimize marketing strategies to improve market share and sales scale[62]. - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming quarters[175]. - The company aims to enhance operational efficiency through strategic mergers and acquisitions in the upcoming quarters[172].

江苏辉丰生物农业股份有限公司 2022 年第一季度报告全文 证券代码：002496 证券简称：ST 辉丰 公告编号：2022-029 追溯调整或重述原因 江苏辉丰生物农业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 同一控制下企业合并 | | 本报告期 | 上年同期 | | 本报告期比上年 同期增减 | | --- | --- | --- | --- | --- | | | | 调整前 | 调整后 | 调整后 | | 营业收入（元） | 64,110,688.79 | 437,379,664.6 ...

Financial Performance - The company reported a significant fluctuation in total profit for the period, with an overall importance level for the consolidated financial statements set at 20.02 million yuan[7]. - The average total profit over the last three years was approximately 400.40 million yuan, which was used as a basis for determining the importance level of the financial statements[7]. - The company's operating revenue for 2021 was CNY 1,095,481,169.58, a decrease of 35.14% compared to CNY 1,688,964,801.86 in 2020[36]. - The net profit attributable to shareholders for 2021 was CNY 307,740,641.70, a significant increase of 207.99% from a loss of CNY 290,549,528 in 2020[36]. - The cash flow from operating activities decreased by 70.00% to CNY 74,254,869.02 in 2021, down from CNY 249,992,879.21 in 2020[36]. - The basic earnings per share for 2021 was CNY 0.20, compared to a loss of CNY 0.19 in 2020, marking a 205.26% improvement[36]. - Total assets at the end of 2021 were CNY 3,764,024,800, a decrease of 24.30% from CNY 4,967,032,600 at the end of 2020[36]. - The net assets attributable to shareholders decreased by 1.53% to CNY 2,411,882,951.96 at the end of 2021, down from CNY 2,460,271,090 at the end of 2020[36]. - The company experienced a significant drop in revenue from CNY 1,614,790,714.52 in 2020 to CNY 773,289,198.98 after adjustments in 2021[36]. - The company has indicated uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years[36]. Subsidiary Control and Equity Transactions - The company lost control over its subsidiary Shijiazhuang Ruikai Chemical Co., Ltd. since November 1, 2020, due to major disputes regarding the execution of the equity transfer agreement[8]. - The book value of the equity in Shijiazhuang Ruikai at the end of the period was 163.48 million yuan, accounting for 4.35% of the total assets in the consolidated financial statements[10]. - The company transferred 51% equity stakes in both Adama Huifeng (Shanghai) Agricultural Technology Co., Ltd. and Adama Huifeng (Jiangsu) Co., Ltd. to Adama Ltd., realizing disposal gains[9]. - The profit contribution from Shijiazhuang Ruikai for the period from January to October 2020 accounted for 0.86% of the company's total consolidated profit[10]. - The company completed the acquisition of Andermatt Huifeng Jiangsu on December 27, 2021, with a payment of CNY 121,608,100[68]. - The company completed the transfer of 51% equity in Andermatt Huifeng (Jiangsu) Co., Ltd., recognizing a gain of ¥329,234,260.95 from the transaction[101]. - The remaining 49% equity was remeasured at fair value, resulting in a gain of ¥346,401,106.60 after losing control[101]. Environmental Compliance and Litigation - The company faced ongoing litigation related to previous environmental regulation violations, which may significantly impact its financial condition and operating results[12]. - The company recognized an impairment provision for the main production equipment of its subsidiaries, totaling approximately 10,967 million CNY, due to prolonged shutdowns and inability to meet environmental and safety standards[14]. - In 2021, the company added an environmental remediation provision of 6,110 million CNY, bringing the cumulative expenditure on environmental control and remediation to 10,858 million CNY, with a remaining balance of 6,219 million CNY as of year-end[14]. - The company faced a lawsuit with a total claim amount of approximately 13,267.50 million CNY, resulting in an additional provision of 1,092.70 million CNY based on a court ruling that required the company to pay 8,770.70 million CNY in compensation and legal fees[15]. - The company is currently undergoing environmental control and remediation processes, which may significantly impact its financial status and operating results[188]. - The company has established various environmental management systems, including wastewater and waste gas management, to ensure compliance with legal and industry standards[173]. - The company has no reported administrative penalties for environmental issues during the reporting period, indicating effective compliance[175]. Research and Development - The company is actively engaged in R&D for environmentally friendly and efficient agricultural solutions, aligning with industry trends towards sustainable practices[47]. - The company has applied for 19 domestic invention patents and has been granted 6, with 6 PCT international invention patents applied for[55]. - Research and development (R&D) expenses decreased by 18.04% to ¥28,867,114.55 compared to the previous year[72]. - The total R&D investment was ¥41,168,147.50, which is 3.76% of the operating revenue, an increase of 1.07% from the previous year[73]. - The number of R&D personnel decreased by 90.29% to 30, significantly impacting the company's R&D capacity[73]. Corporate Governance and Management - The company maintains complete independence from its controlling shareholders in terms of business, assets, personnel, and finance[111]. - The company has established an independent financial accounting department and a complete accounting system, ensuring no mixed taxation with shareholders[113]. - The company has a robust corporate governance structure that complies with relevant laws and regulations[110]. - The company has appointed new independent directors, ensuring compliance with governance standards[118]. - The company has undergone significant personnel changes, including the resignation of several board members and senior management due to major asset restructuring[119]. - The company has a strong management team with extensive experience in the agricultural chemical industry, including key figures like Zhong Hangen and Pei Boping[121][122]. Social Responsibility and Community Engagement - The company was recognized as the "Most Beautiful Caring Enterprise" by the Charity Association of Dafeng District, Yancheng City in 2021[179]. - The company donated agricultural disaster relief materials to Lankao County, Henan Province, in August 2021, actively participating in disaster relief efforts[179]. - The company contributed to the Jiangsu Guangcai Charity Foundation, promoting social poverty alleviation and public welfare initiatives[179]. - The company is involved in the "Love Aid Tibet" initiative, aligning with national poverty alleviation and rural revitalization efforts[179]. Internal Control and Audit - The company has established a comprehensive internal control system that is effective and updated according to regulatory requirements, with no significant internal control deficiencies reported during the period[152]. - The internal control self-assessment report for 2021 indicates that 100% of the company's total assets and revenue were included in the evaluation scope[154]. - There were no major or important deficiencies identified in the internal control system during the reporting period, with zero instances reported for both financial and non-financial reports[156]. - The internal control audit report confirms that the company maintained effective financial reporting internal controls as of December 31, 2021[158]. - The audit report indicated no significant deficiencies in non-financial reporting controls[167].

江苏辉丰生物农业股份有限公司 2021 年第三季度报告 证券代码：002496 证券简称：ST辉丰 公告编号：2021-098 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 董事、监事、高级管理人员是否存在对季度报告内容存在异议或无法保证其真实、准确、完整的情况 □ 是 √ 否 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 4.审计师发表非标意见的事项 □ 适用 √ 不适用 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增减 | 年初至报告期末 | 年初至报告期末比上年 | | | --- | --- | --- | --- | --- | --- | | | | ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥720,624,842.06, a decrease of 6.42% compared to ¥770,031,190.62 in the same period last year[19]. - The net profit attributable to shareholders of the listed company reached ¥545,303,078.04, a significant increase of 1,228.03% compared to a loss of ¥48,341,324.99 in the previous year[19]. - The basic earnings per share improved to ¥0.36, compared to a loss of ¥0.03 per share in the same period last year, marking a 1,300.00% increase[19]. - The total revenue for the reporting period was ¥720,624,842.06, a decrease of 6.42% compared to the previous year[39]. - The company reported a significant increase in investment cash flow, with a net amount of ¥549,473,825.97, up 8,267.69% due to equity transfer proceeds[39]. - The company reported a net profit of CNY 359,790,104.07, compared to a net loss of CNY 183,954,368.73 in the previous period[158]. - The company achieved an investment income of CNY 719,822,199.84, a substantial increase from CNY 24,625,381.45 in the same period last year[163]. - The net profit for the first half of 2021 was CNY 186,594,877.44, a significant increase from CNY 1,969,650.24 in the first half of 2020[170]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,368,837,710.05, down 12.04% from ¥4,967,032,607.21 at the end of the previous year[19]. - Total liabilities decreased to CNY 1,670,844,651.33 from CNY 2,581,112,766.44, a reduction of approximately 35.3%[157]. - The company's equity increased to CNY 2,697,993,058.72 from CNY 2,385,919,840.77, showing an increase of about 13.0%[158]. - Cash and cash equivalents decreased to ¥277,103,349.8, representing 6.34% of total assets, down from 8.46% at the end of the previous year, a decrease of 2.12%[46]. - Accounts receivable amounted to ¥249,827,707.9, accounting for 5.72% of total assets, down from 7.25% previously, a decrease of 1.53%[46]. - Inventory decreased to ¥277,472,016.5, representing 6.35% of total assets, down from 12.87%, a decrease of 6.52%, mainly due to the disposal of subsidiaries during the reporting period[46]. Cash Flow - The company reported a net cash flow from operating activities of -¥20,067,635.45, a decrease of 123.36% compared to ¥85,919,913.47 in the same period last year[19]. - The cash flow from operating activities showed a net outflow of CNY 20,067,635.45 in the first half of 2021, compared to a net inflow of CNY 85,919,913.47 in the same period of 2020[173]. - The cash flow from investing activities generated a net inflow of CNY 549,473,825.97 in the first half of 2021, a recovery from a net outflow of CNY 6,727,409.43 in the first half of 2020[174]. - The cash flow from financing activities resulted in a net outflow of CNY 703,127,114.79 in the first half of 2021, compared to a net inflow of CNY 111,831,042.24 in the same period of 2020[174]. Environmental and Regulatory Compliance - Jiangsu Huifeng reported a total wastewater discharge of 64.6384 tons per year, with a chemical oxygen demand (COD) concentration of 196.73 mg/L, meeting the discharge standards[73]. - The company has established seven RTO incinerators for the treatment of organic waste gas, ensuring stable compliance with emission standards[75]. - The company has received environmental approvals for multiple projects, including the technical transformation of fluazifop-p-butyl and glyphosate raw materials, all approved on January 26, 2021[76]. - The company has implemented a comprehensive environmental monitoring system, including online monitoring for wastewater and waste gas, with third-party verification conducted annually[77]. - The company has been under environmental scrutiny, leading to the suspension of operations at certain facilities since 2018[115]. Research and Development - The company has filed for 72 domestic and 103 overseas product invention patents, indicating strong R&D capabilities[33]. - The company has applied for 19 domestic invention patents in the biopesticide sector, with 6 granted and 3 PCT international patents applied for[34]. - The biopesticide product "Neng Bai Wang" has been registered for use on 13 types of crops, demonstrating significant yield increase in field trials[34]. - Research and development expenses increased to CNY 19,816,822.74, up 38.5% from CNY 14,346,602.62 in the first half of 2020[163]. Corporate Governance and Legal Matters - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[84]. - The total amount claimed by investors against Huifeng Co. for false statements related to environmental regulations is 132.67 million yuan, with a provision of 76.78 million yuan recorded by the company[91]. - As of July 16, 2021, the court ruled that Huifeng Co. must pay a total of 87.71 million yuan in compensation, including legal fees, leading to an additional provision of 10.93 million yuan in the reporting period[91]. - The company has ongoing litigation with Hebei Baishida Trading Co. regarding equity transfer disputes, with an amount involved of 54.05 million yuan, but it is not expected to significantly impact the company's performance[95]. Strategic Initiatives - The company is focusing on the development of biological agricultural products and has established a leading domestic bio-fermentation laboratory[27]. - The company aims to leverage its partnership with ADAMA to enhance its operational capabilities and market position in the agricultural sector[33]. - The company plans to continue expanding its market presence in the agricultural chemicals sector, focusing on new product development and technological advancements[191].

Financial Performance - The company reported a significant fluctuation in total profit for the period, with a calculated overall importance level for the consolidated financial statements set at CNY 46.3 million, based on an average profit total of CNY 463.06 million over the last three years[5]. - The company's operating revenue for 2020 was CNY 1,641,807,709.57, representing a 33.87% increase compared to CNY 1,226,380,348.53 in 2019[19]. - The net profit attributable to shareholders was a loss of CNY 290,549,528.54, an improvement of 42.34% from a loss of CNY 503,927,660.02 in 2019[19]. - The net cash flow from operating activities increased by 110.08% to CNY 249,992,879.21 from CNY 119,001,312.58 in the previous year[19]. - The total assets at the end of 2020 were CNY 4,967,032,607.21, down 8.27% from CNY 5,414,840,419.50 at the end of 2019[19]. - The net assets attributable to shareholders decreased by 8.74% to CNY 2,460,271,092.32 from CNY 2,695,804,351.81 in 2019[19]. - The basic earnings per share improved to -CNY 0.19 from -CNY 0.33 in 2019, a 42.42% increase[19]. - The company reported a net loss of ¥66,550,845.26 for the reporting period[27]. - The company reported a loss of ¥353,522,719.59 in net profit for 2020, an improvement from a loss of ¥586,270,586.52 in 2019[68]. Environmental and Legal Issues - The company is currently facing litigation related to false statements regarding environmental regulation violations, with total claims amounting to CNY 132.68 million[6]. - The company is under ongoing environmental and safety production risks, which may affect future operations and financial performance[7]. - The company has recognized a provision for litigation compensation amounting to CNY 76.78 million, pending the outcome of ongoing legal proceedings[6]. - The audit report for 2020 included a qualified opinion due to ongoing environmental compliance issues and related lawsuits, which may significantly impact the company's financial status and operating results[124]. - The company has faced production interruptions due to environmental regulation violations, with some subsidiaries still not operational as of the report date[127]. - The company has acknowledged significant accounting errors from 2013-2015 due to environmental violations, resulting in the cancellation of its high-tech enterprise qualification and necessitating tax adjustments totaling approximately ¥78.48 million[140]. Revenue and Sales Performance - Revenue from pesticides and intermediates accounted for 85.86% of total revenue, amounting to CNY 1,409,626,637.24, up 52.51% compared to CNY 924,303,243.07 in 2019[51]. - Export revenue surged by 170.16% to CNY 669,358,199.29, while domestic sales slightly decreased by 0.63% to CNY 972,449,510.28[51][54]. - The production volume of pesticide products increased by 125.42% to 20,551.76 KG/L, while sales volume rose by 67.42% to 20,574.09 KG/L[55]. - The gross profit margin for pesticides and intermediates was 23.49%, with a significant increase in revenue and cost compared to the previous year[53]. - The company’s pesticide raw materials and intermediates generated CNY 968,378,603.79 in revenue, representing 58.98% of total revenue, with an 89.47% increase year-on-year[51]. Investment and Capital Management - The company plans not to distribute cash dividends, issue bonus shares, or increase capital through reserves for the reporting period[7]. - The total investment amount for the reporting period was RMB 355,529,142.62, representing a year-on-year increase of 28.63% compared to RMB 276,395,327.15[79]. - The company has terminated the implementation of certain fundraising projects, reallocating the remaining funds to enhance operational efficiency[85]. - The company has completed the production of several projects, including a 3,000-ton annual production project for Mefenacet and a 1,000-ton project for Dithiocarbamate[39]. - The company plans to permanently supplement working capital with the remaining raised funds, which were not invested as of September 29, 2020[91]. Research and Development - The company reported a decrease in R&D investment to 45,388,085.70 CNY in 2020, down 20.89% from 57,375,761.58 CNY in 2019, with R&D personnel decreasing by 7.21%[64]. - The proportion of R&D investment to operating income was 2.76% in 2020, a decrease of 1.92% compared to 4.68% in 2019[65]. - The company has a complete research and development, procurement, production, testing, and sales system to support its operations[33]. - The company is focused on developing new products and technologies to enhance its competitive edge in the agricultural sector[43]. Safety and Compliance - The company has established a comprehensive environmental management system, including regulations for wastewater and air emissions management, ensuring compliance with legal standards[178]. - The company has implemented a comprehensive hidden danger investigation and rectification plan based on hazardous chemical safety guidelines[173]. - The company has established a safety management department and employed 7 registered safety engineers for technical support[173]. - The company conducted 27 emergency rescue drills during the reporting period to enhance safety management[174]. - The company has received over 30 inspections from government safety and fire supervision departments during the reporting period[173]. Shareholder and Governance - The company has established a profit distribution policy, ensuring that at least 10% of the distributable profit is allocated to shareholders annually[108]. - The cash dividend policy is designed to maintain continuity and stability, with a minimum of 30% of the average distributable profit over any three consecutive years being distributed[109]. - The company’s profit distribution policy is subject to review and approval by the board of directors and shareholders, ensuring compliance with regulations[112]. - The company has not engaged in any investor communication activities during the reporting period[106]. - The company has fulfilled its commitments related to stock lock-up and avoiding competition as per the commitments made by its actual controller, with no non-operating fund occupation by major shareholders[122].